Global Breast Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centers, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others) Industry Trends and Forecast to 2030.
Breast Cancer Diagnostics Market Analysis and Insights
Breast cancer is the most common disease in the population, occurring mainly in women with proliferative diseases. Breast cancer develops mainly in the breast tissues. Symptoms of breast cancer include lumps in the breast, a difference in the size and shape of the breasts, discharge from the nipples, and irritated, scaly red patches on the skin. The incidence of breast cancer in women increases every time the growth of the breast cancer market increases with the growth of drugs. Advanced methods for diagnosis of breast cancer with developed techniques. Improving the technologies developed in breast cancer by increasing the effectiveness, accuracy, efficiency, reliability and speed of results and improving the detection of disorders. Advanced features to detect cancer in less time. Cancer is detected at an early stage, which helps patients recover faster, prevent cancer cells from spreading to other parts of the body, and treat them with new drugs on the market. Increased tumor screening and imaging will drive the breast cancer market. This is expanding the breast cancer market with an increasing number of patients every year, and the rate of recovery from breast cancer is increasing. Government support by increasing the availability of new drug development projects and increasing the effectiveness and efficiency of treatment and the integration of new drugs into the medical field.
However, the high cost of cancer diagnostic treatments and the lack of skilled professionals are the factors that are restraining the market growth.
Data Bridge Market Research analyzes that the global breast cancer diagnostics market is expected to reach the value of USD 8,651.50 million by 2030, at a CAGR of 9.2% during the forecast period. Test type accounts for the largest diagnostic type segment in the market due to rising breast cancer patients and technological advancements in treatment of breast cancer globally. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2020-2016)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centers, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others).
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Belgium, Turkey, Ireland and Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines and Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel and Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.
|
|
Market Players Covered
|
The major companies which are dealing in the market are F-Hoffmann La Roche Ltd., Siemens Healthcare GmbH, General Electric, Koninklijke Philips N.V., FUJIFILM Corporation, Abbott, Hologic, Inc., OncoStem, Provista Diagnostics, Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., BD, NanoString., Cepheid, BIOMÉRIEUX, Exact Sciences Corporation, Biocept, Inc., and Abacus ALS, among others.
|
Global Breast Cancer Diagnostics Market Definition
Breast cancer is a disease in which the uncontrolled growth of malignant cells in the breast tissue occurs more often in women than in men. Breast cancer is the uncontrolled cell division of breast cells, which are the most common cells in the mammary glands and ducts. Some symptoms of breast cancer include a lump or lump in the breast, bloody discharge from the nipple and a change in the shape of the nipple or breast. Breast cancer treatment depends on the stage of cancer. Its treatment consists of chemotherapy, radiation therapy, hormone therapy, and surgery.
Breast cancer is another type of cancer that is more common in women than in men. A number of the symptoms of the sickness hold bleeding secretion from the reproductive organ, a lump or block within the breast, and variations in the texture or form of the breast or nipple. Breast cancer treatment depends on the stage of cancer. In addition, its treatment includes radiotherapy, therapy, hormone therapy and surgery. Early detection of carcinoma is essential for the effective treatment of the disease. Early detection of the disease also leads to better outcomes, including many treatment options, better survival and better quality of life. Increasing pressure and demand for new forms of treatment or methods of treatment are due to the rapidly increasing spread of diseases.
Global Breast Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Launch of technologically advanced diagnosis & therapeutics to aid growth
Breast cancer is the most common disease in the population, occurring mainly in women with proliferative disease. Breast cancer develops in the breast tissues. Symptoms of breast cancer include lumps in the breast, differences in the size and shape of the breast, discharge from the nipples, and itchy, scaly red patches on the skin. This disease spreads in body with increasing symptoms such as bone pain, swollen lymph nodes, difficulty in breathing and many others. Increasing research and development with new technologies and treatments developed for breast cancer will significantly contribute to market growth.
Moreover, Technological advances in imaging are creating new opportunities for improvements in both screening and early detection. One technology advance is 3-D mammography, also called breast tomosynthesis. This procedure takes images from different angles around the breast and builds them into a 3-D-like image.
In the recent times, several advancements in technology is changing the fate of cancer diagnostics, as mentioned above some of the recent advancements, several other technologies are currently under trial phase which are on the limit of changing the process of breast cancer diagnostics. These technological advancements in the field are acting as a major drivers for global breast cancer diagnostics market.
- Increasing prevalence of breast cancer
One of the major factors driving the growth of the global market is the increasing prevalence of breast cancer worldwide, which is expected to lead to a large number of patients in need of accurate and effective treatment options. Breast cancer is one of the most common cancers in the world, and better diagnostics are expected to increase the number of patients diagnosed in the future.
In addition, the growing demand for preventive care and early treatment has led to many cancer screenings, which would also increase the number of patients with a high need for treatment during the forecast period.
Thus, increasing prevalence of breast cancer leads to more diagnosis of cases and hence it is expected to drive the market growth during the forecast period.
Restraint
- Adverse effects of breast cancer therapeutics
Screening is looking for cancer before a person has any symptoms. This can help find cancer at an early stage. When abnormal tissue or cancer is found early, it may be easier to treat. By the time symptoms appear, cancer may have begun to spread. Several screening tests are used for detecting breast cancers which include breast magnetic resonance imaging, diagnostic mammogram, biopsy etc. Although these test are considered to be standard for diagnosing breast cancer, they have their associated risks which include false-negative results, false-positive results, and side effects such as undue psychological stress, excessive radiation exposure, and a serious risk of tumor rupture and spread of cancerous cells.
Opportunity
- Initiatives taken by the government
Government is focusing on increasing the initiative for breast cancer treatments with advanced techniques to improve the health of patients. Providing he number of insurances, such as benefits, has been increased so that ordinary people can choose treatment and take advantage of available medicines and treatments to improve their quality of life. In developing countries such as China and India, the government has launched several programs and initiatives to raise awareness about the disease. This has greatly increased the demand for breast cancer diagnosis and disease management therapies. Increasing mergers and acquisitions between pharmaceutical companies and government agencies are among the main trends in the global breast cancer market.
Rates of new breast cancer cases have risen 0.6% per year from 2010-2019, and death rates have risen an average of 1.7% per year for the same time frame. As the breast cancer patient rate is increasing, the use of treatments and advanced technologies for the diagnosis of cancer will increase, which is an opportunity for market growth.
Challenge
- Lack of diagnostic infrastructure
Non-communicable diseases such as breast cancer and other types of cancer have now been recognized by the United Nations and WHO as a major public health crisis. Cancer is the biggest part of this problem, and health systems face a major challenge to improve cancer care, control costs and increase system efficiency. Differences in treatment approach and outcomes between high income countries and low and middle income countries are striking. Reasons for this disparity include cost, access to care, workforce and training gaps, and lack of awareness among the lay and medical community.
Moreover, compared to early diagnosis, cancer screening is a separate and more complex public health strategy that requires additional resources, infrastructure and coordination. Rural, developing and low income countries in the different regions does not have enough infrastructure to maintain with the new kits and fro the sample storage as well. These countries need diagnostic infrastructure to ensure the early detection and rapid, accurate diagnosis of the disease.
Post-COVID-19 Impact on Global Breast Cancer Diagnostics Market
The COVID-19 pandemic has caused disruptions in elective health services related to breast screening, pre-cancer care and management of abnormal screening results. This could lead to an increase in the incidence of breast cancer, exacerbating existing health inequalities.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the market.
Recent Developments
- In November 2022, Koninklijke Philips N.V., announced the global launch of a next-generation compact portable ultrasound solution at the Radiological Society of North America (RSNA) annual meeting to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients. It is portable and versatile with good image quality or performance. It is Compatible with Philips ultrasound systems Affiniti and EPIQ transducer. This has helped company to expand its product portfolio.
- In November 2022, Siemens Healthineers and Atrium Health, a leading not-for-profit healthcare provider known for leading pediatric, cancer and cardiac care programs, have announced a multi-year value partnership1. This strategic agreement focuses on improving access to care in Atrium Health's service area in the southeastern United States, improving health equity and increasing economic mobility. Atrium Health is acquiring more than $140 million in equipment and devices from Siemens Healthineers, including advanced imaging technology, radiation oncology and precision endovascular robotics. This has helped the company to expand their business.
Global Breast Cancer Diagnostics Market Scope
Global breast cancer diagnostics market is segmented into test type, type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE
- IMAGING
- BIOPSY
- GENOMIC TEST
- BLOOD TEST
- OTHERS
On the basis of test type, the global breast cancer diagnostic market is segmented into imaging, biopsy, genomic test, blood tests and others.
GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY TYPE
- DUCTAL CARCINOMA IN SITU
- INVASIVE DUCTAL CARCINOMA
- INFLAMMATORY BREAST CANCER
- METASTATIC BREAST CANCER
On the basis of type, the global breast cancer diagnostic market is segmented into ductal in situ carcinoma, invasive ductal carcinoma, inflammatory breast cancer, and metastatic breast cancer.
GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY END USER
- HOSPITALS
- CLINICS
- RESEARCH & ACADEMIC INSTITUTES
- DIAGNOSTIC CENTERS
- OTHERS
On the basis of end user, the global breast cancer diagnostic market is segmented into hospitals, clinics, research and academic institutes, diagnostic centers and others.
GLOBAL BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
- DIRECT TENDER
- RETAIL SALES
- OTHERS
On the basis of distribution channel, the global breast cancer diagnostic market is segmented into direct tender, retail sales and others.
Global Breast Cancer Diagnostics Market Regional Analysis/Insights
The global breast cancer diagnostics market is analyzed and market size information is provided test type, type, end user, and distribution channel.
- In 2023, North America is dominating due to the presence of key market players in the largest consumer market with high GDP. The U.S. is expected to grow due to its latest advanced cancer diagnostic technology and inventions in the breast cancer diagnostics.
North America is dominating the market due to the increasing investment in R&D of breast cancer is expected to boost the market growth. The U.S. dominates North America region due to strong presence of key players are F-Hoffmann La Roche Ltd., Siemens Healthcare GmbH, General Electric, Koninklijke Philips N.V., ABBOTT and others. U.K. dominates Europe region due to the mass production of breast cancer diagnostics drugs and increasing demand from emerging markets and expansion of cancer treatment industries. China dominates Asia-Pacific region due to rise in breast cancer mainly among the women population as well as men.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Breast Cancer Diagnostics Market Share Analysis
Global breast cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the global breast cancer diagnostics market.
Some of the major players operating in the global breast cancer diagnostics market are F-Hoffmann La Roche Ltd., Siemens Healthcare GmbH, General Electric, Koninklijke Philips N.V., FUJIFILM Corporation, Abbott, Hologic, Inc., OncoStem, Provista Diagnostics, Thermo Fisher Scientific Inc., Myriad Genetics, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., BD, NanoString., Cepheid, BIOMÉRIEUX, Exact Sciences Corporation, Biocept, Inc., and Abacus ALS.
SKU-